Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.
Reduction of intracranial pressure,Reduction of cerebral edema,Promotion of diuresis in oliguric phase of acute renal failure
Reduction of intracranial pressure,Reduction of intraocular pressure,Promotion of diuresis in oliguric acute renal failure (prophylaxis or treatment),Osmotic diuresis for drug overdose (e.g., salicylates, barbiturates),Irrigation solution during transurethral prostatic resection
Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.
Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.
Terminal half-life approximately 1.5 hours in normal renal function; prolonged in renal impairment (up to 36 hours in anuria).
Terminal elimination half-life of mannitol is approximately 1.5-2 hours in patients with normal renal function. Clinically, duration of osmotic diuresis parallels half-life; in renal impairment, half-life may extend to 24-36 hours, increasing risk of fluid overload and electrolyte disturbances.
Primarily excreted unchanged by the kidneys; not metabolized.
Mannitol is not significantly metabolized; it is excreted unchanged by the kidneys. Dextrose is metabolized via glycolysis to pyruvate and lactic acid, and enters the Krebs cycle for energy production.
Primarily renal; >90% excreted unchanged in urine via glomerular filtration; <5% biliary/fecal.
Primarily renal excretion: Mannitol is filtered by glomeruli and not reabsorbed, excreted unchanged in urine (approximately 80-90% within 24 hours). Biliary/fecal elimination is negligible (<5%). Dextrose is metabolized to CO2 and water; any excess is excreted renally as glucose if threshold exceeded.
Negligible (<10%); does not significantly bind to plasma proteins.
Mannitol is not significantly bound to plasma proteins (<1%). Dextrose is not protein bound.
Vd ~0.5 L/kg; distributes primarily in extracellular fluid, excluding cells.
Approximately 0.5-0.6 L/kg. Mannitol distributes primarily in extracellular fluid (ECF); it does not enter cells significantly. Clinically, this low Vd indicates confinement to ECF, important for osmotic effects.
Not applicable (administered intravenously only); bioavailability is 100% by IV route.
Intravenous: 100% bioavailability. Oral bioavailability is negligible (<10%) as mannitol is poorly absorbed and acts as an osmotic laxative; Dextrose is well absorbed orally (100%) but not relevant for this IV formulation.
Contraindicated in anuria or severe renal impairment (GFR <10 m L/min). In patients with GFR 10–50 m L/min, reduce dose by 50% and monitor serum osmolarity and urine output. Do not use if oliguria persists after test dose (0.2 g/kg IV over 3–5 minutes).
Contraindicated in anuria or severe renal impairment (GFR < 20 m L/min). For GFR 20-50 m L/min, use with caution and monitor serum osmolality; reduce dose or extend interval. No specific dose reduction formula established.
No specific Child-Pugh based adjustment. Use with caution in severe hepatic impairment due to potential for fluid overload and electrolyte disturbances. Monitor serum electrolytes and hepatic function.
No specific adjustments required for hepatic impairment. Monitor fluid and electrolyte balance due to potential volume expansion.
Oliguria: Test dose 0.2 g/kg (2 m L/kg of 10% solution) IV over 3–5 minutes. If urine output >40 m L/hr, maintenance dose: 0.25–1 g/kg (2.5–10 m L/kg) IV over 30–60 minutes every 6–12 hours. Maximum: 2 g/kg per dose. Reduce intracranial pressure: 0.25–1 g/kg IV over 30–60 minutes.
0.25-1 g/kg (2.5-10 m L/kg of 10% solution) intravenously over 30-60 minutes, repeated as needed. Max dose 2 g/kg/day. Adjust based on response and serum osmolality.
Start at lower end of dosing range (0.25 g/kg) due to age-related decline in renal function. Monitor renal function, serum osmolarity, electrolytes (especially sodium and potassium), and fluid balance closely. Avoid use if GFR <50 m L/min unless benefit outweighs risk.
Use lower initial doses and monitor renal function and electrolytes closely due to age-related decline in renal function and higher risk of volume overload. Start at 25-50 g (250-500 m L of 10% solution) and titrate.
Not approved for use in patients with severe renal impairment, anuria, or intracranial hemorrhage with active bleeding.
None.
Monitor renal function, fluid and electrolyte balance, and serum osmolality. Use caution in patients with cardiac or pulmonary congestion, and administer via a filter to prevent crystallization.
Monitor serum electrolytes, osmolality, and renal function during therapy,May cause fluid and electrolyte imbalances, including hyponatremia or hypernatremia,Administer cautiously in patients with renal impairment, heart failure, or pulmonary edema,Use with caution in conditions where increased intravascular volume may be harmful,Do not administer if solution contains particulate matter or is discolored
Anuria, severe renal impairment, pulmonary congestion, active intracranial hemorrhage, severe dehydration, known hypersensitivity to mannitol.
Anuria due to severe renal disease,Severe dehydration,Intracranial hemorrhage (unless during craniotomy),Active intracranial bleeding except during craniotomy,Hypersensitivity to mannitol or dextrose,Congestive heart failure,Pulmonary edema
No specific food interactions. Maintain adequate hydration as directed. Avoid excessive salt intake to minimize fluid retention.
No clinically relevant food interactions.
Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, use only if clearly needed. In second and third trimesters, mannitol can cross the placenta and may cause fetal dehydration, electrolyte disturbances, and osmotic shifts. Risk cannot be excluded.
No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. First trimester: theoretical risk only, no reported malformations. Second/third trimesters: monitor for maternal hyperosmolality and fluid shifts which may affect fetal hydration status.
It is not known whether mannitol is excreted in human breast milk. No M/P ratio is available. Caution should be exercised when administered to a nursing woman. Consider the developmental and health benefits of breastfeeding alongside the mother's clinical need for the drug.
Not known if mannitol or dextrose are excreted in breast milk. Consider risk of osmotic diarrhea in neonate if present in milk. M/P ratio not established.
Pregnancy increases glomerular filtration rate, which may enhance mannitol elimination, but dosage adjustments are not established. Maintain standard dosing (generally 50-200 g over 24 hours). Monitor clinical response and urine output. No routine pharmacokinetic-based dose adjustment recommended.
No specific dose adjustment recommended; monitor maternal fluid status closely as pregnancy increases risk of pulmonary edema; adjust rate based on urine output and osmolality.
Osmítrol 10% is a hyperosmotic agent used to reduce intracranial pressure and cerebral edema. Administer via IV infusion using an in-line filter to prevent particulate embolism. Monitor serum osmolarity and sodium levels; discontinue if osmolarity exceeds 320 m Osm/L. Ensure adequate hydration to avoid hypovolemia. Use with caution in patients with renal impairment, congestive heart failure, or pulmonary congestion. Crystallization may occur at low temperatures; warm to redissolve crystals before use.
Monitor serum sodium and osmolality closely; risk of hypernatremia and acute kidney injury. Use an in-line filter to prevent crystallization. Administer by slow IV infusion to avoid fluid overload. Contraindicated in anuria and severe pulmonary edema.
This medication is given intravenously to reduce swelling in the brain.,You may experience a headache, nausea, or increased thirst during infusion.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,You will be monitored with blood tests to check kidney function and electrolyte levels.,Avoid rapid position changes to prevent dizziness due to fluid shifts.,Do not stop this medication abruptly; follow your healthcare provider's instructions.
Report any signs of fluid overload like shortness of breath or swelling.,This medicine may cause increased urination and thirst.,Do not take this medication by mouth; it is for intravenous use only.,Inform your healthcare provider if you have kidney problems or heart failure.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSMITROL 10% IN WATER IN PLASTIC CONTAINER vs MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER, answered by our medical review team.
OSMITROL 10% IN WATER IN PLASTIC CONTAINER is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from tissues into the bloodstream, thereby reducing intracranial pressure and cerebral edema.. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is a Osmotic Diuretic that works by Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular spaces into the extracellular fluid and bloodstream, thereby reducing cerebral edema and promoting diuresis. Dextrose provides a source of calories and may help prevent hypoglycemia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER depend on the specific clinical indication. These are both Osmotic Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSMITROL 10% IN WATER IN PLASTIC CONTAINER is: Initial: 0.25–1 g/kg (25–100 m L of 10% solution) IV over 30–60 minutes. May repeat every 6–12 hours if needed. Typical adult dose: 50–100 g IV. Maximum: 2 g/kg per dose.. The standard adult dose of MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is: Adult: 50-100 g (500-1000 m L of 10% solution) intravenously over 1-2 hours, repeated as needed every 6-12 hours. Individualize based on urine output and serum osmolality.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSMITROL 10% IN WATER IN PLASTIC CONTAINER and MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSMITROL 10% IN WATER IN PLASTIC CONTAINER is classified as Category C. Osmitrol 10% (mannitol) is a hyperosmolar agent. There are no adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. In first trimester, us. MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER is classified as Category A/B. No evidence of teratogenicity in animal studies; limited human data. Mannitol crosses the placenta; risk of fetal electrolyte disturbances and dehydration with maternal overdose. F. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.